AJMC® in the Press, November 22, 2019

November 22, 2019

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

An article appearing in Nashville Medical News and shared by Tennessee Oncology and OneOncology, titled “The Oncology Care Model Value Proposition,” highlighted 2 meetings, Patient-Centered Oncology Care® in Philadelphia, Pennsylvania, and the Institute for Value-Based Medicine® (IVBM) in Nashville, Tennessee, conducted by The American Journal of Managed Care® (AJMC®). The article spotlighted the presentation of featured IVBM speaker Stephen Schleicher, MD, MBA, physician and Tennessee Oncology’s chair of the Quality and Value Committee at OneOncology.

Endpoints News referenced an article from AJMC®’s sister site, The Center for Biosimilars®, titled “AbbVie and Boehringer Ingelheim Settle Over Biosimilar Adalimumab.” The article detailed the announcement of AbbVie's patent litigation settlement with Boehringer Ingelheim over the biosimilar Cyltezo, which references AbbVie’s originator adalimumab, Humira.

Another article from The Center for Biosimilars® was also featured in the November 18, 2019 daily regulatory news and intelligence briefing from Regulatory Focus. The article, “Biosimilars Make Progress in the Canadian Market, but Stakeholders See More Work Ahead,” was included in the In Focus: International section. The article emphasized strides made by Canada in its biosimilar experience.

An article in Williston Herald,A New Way to Fight Breast Cancer,” highlighted an AJMC® article, “FDA Approves First Breast Cancer Drug to Target PIK3CA Mutation Plus Companion Diagnostic Test.” The article covered the announcement by the FDA of the approval for the novel oral drug alpelisib, sold as Piqray.